Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Status:
Recruiting
Trial end date:
2022-07-11
Target enrollment:
Participant gender:
Summary
Infections are a major life-threatening complication in patients with myelodysplastic
syndrome (MDS) or acute myeloid leukaemia (AML). Currently there is no guidelines about
antibacterial prophylaxis to prevent infections in patients with myelodysplastic syndrome or
acute myeloid leukaemia. The investigators will conduct a randomized prospective study to
evaluate the benefit of prophylactic antibacterial by levofloxacin on febrile episode in
Azacytidine treated patients (MDS and AML).